PMCPA Case
| Case number | AUTH/2235/5/09 |
| Parties | Cephalon/Director v ProStrakan |
| Product | Abstral (sublingual fentanyl citrate tablet) |
| Material/channel | BMJ advertisement (18 April 2009), ref MO17/0134; date of preparation March 2009 |
| Main claims at issue | “To hell and back in minutes”; “Acts in minutes”; also “Dissolves in seconds. Acts in minutes” |
| SPC timing referenced by Panel | Relief from 15 minutes after administration onwards (SPC 5.1); dosing guidance 15–30 minutes (SPC 4.2) |
| Applicable Code year | 2008 |
| Breach clauses | 2, 3.2, 7.2, 9.1 and 25 |
| Complaint received | 28 May 2009 |
| Undertaking received | 3 July 2009 |
| Appeal hearing | No appeal by either party; Panel referred to the Appeal Board |
| Appeal Board considerations | 23 July 2009; 24 February 2010; 22 July 2010 |
| Interim case report published | 26 August 2009 |
| Case completed | 22 July 2010 |
| Sanctions applied | Undertaking received; Advertisement; Audit of company’s procedures; Re-audit |
Download the full case report (PDF)
Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory
Got a question about this case?
Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.
⭐ Business Intelligence Access
See the full compliance picture for every pharma company
291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.
One real case. One key lesson. Every week — free.